EP0594677A4 - Antiviral liponucleosides: treatment of hepatitis b - Google Patents
Antiviral liponucleosides: treatment of hepatitis bInfo
- Publication number
- EP0594677A4 EP0594677A4 EP92914562A EP92914562A EP0594677A4 EP 0594677 A4 EP0594677 A4 EP 0594677A4 EP 92914562 A EP92914562 A EP 92914562A EP 92914562 A EP92914562 A EP 92914562A EP 0594677 A4 EP0594677 A4 EP 0594677A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- liponucleosides
- antiviral
- hepatitis
- treatment
- antiviral liponucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73027391A | 1991-07-12 | 1991-07-12 | |
| US730273 | 1991-07-12 | ||
| PCT/US1992/004856 WO1993000910A1 (en) | 1991-07-12 | 1992-06-03 | Antiviral liponucleosides: treatment of hepatitis b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0594677A1 EP0594677A1 (en) | 1994-05-04 |
| EP0594677A4 true EP0594677A4 (en) | 1997-09-17 |
Family
ID=24934656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP92914562A Withdrawn EP0594677A4 (en) | 1991-07-12 | 1992-06-03 | Antiviral liponucleosides: treatment of hepatitis b |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0594677A4 (en) |
| JP (1) | JPH07500573A (en) |
| AU (1) | AU668873B2 (en) |
| CA (1) | CA2112803A1 (en) |
| WO (1) | WO1993000910A1 (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105244A (en) * | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
| US6413949B1 (en) * | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| US5484911A (en) * | 1993-04-01 | 1996-01-16 | Health Research, Inc. | Nucleoside 5'-diphosphate conjugates of ether lipids |
| DE4321978A1 (en) * | 1993-07-01 | 1995-01-12 | Boehringer Mannheim Gmbh | Liponucleotides of deoxynucleosides, their production and their use as antiviral drugs |
| US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
| JP4259611B2 (en) | 1994-08-29 | 2009-04-30 | ウェイク フォレスト ユニバーシティ | Lipid analogues for treating viral infections |
| US7135584B2 (en) | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
| US6313106B1 (en) | 1995-06-07 | 2001-11-06 | D-Pharm Ltd. | Phospholipid derivatives of valproic acid and mixtures thereof |
| DE69636734T2 (en) * | 1995-06-07 | 2007-10-18 | Emory University | NUCLEOSIDE WITH ANTI-HEPATITIS B VIRUS EFFICACY |
| AU2003201382B8 (en) * | 1995-06-07 | 2010-04-29 | Centre National De La Recherche Scientifique | Nucleosides with anti-hepatitis B virus activity |
| EA200700564A1 (en) | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-Fluoride |
| US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| DK2415776T3 (en) | 1998-08-10 | 2016-07-04 | Novartis Ag | Beta-L-2'-deoxy nucleosides for the treatment of Hepatitis B |
| CN1666742A (en) | 1998-11-02 | 2005-09-14 | 三角药物公司 | Combination therapy to treat hepatitis b virus |
| IL127143A0 (en) | 1998-11-19 | 1999-09-22 | Dpharm Ltd | Phospholipid terivatives of non-steroidal anti inflammatory drugs |
| IL131887A0 (en) | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
| KR20080059679A (en) | 2000-03-29 | 2008-06-30 | 조지타운 유니버시티 | Method of treating hepatitis delta viral infection |
| US6761901B1 (en) | 2000-05-02 | 2004-07-13 | Enzrel Inc. | Liposome drug delivery |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20030036189A (en) | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | Methods and compositions for treating flaviviruses and pestiviruses |
| US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US6455073B1 (en) | 2000-07-10 | 2002-09-24 | Enzrel, Inc. | Covalent microparticle-drug conjugates for biological targeting |
| US6689760B1 (en) | 2000-07-10 | 2004-02-10 | Enzrel Inc. | Anti-mycobacterial compositions |
| PT1411954E (en) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
| CN102911166B (en) | 2001-03-01 | 2016-08-17 | 基利得科学公司 | The polymorph of cis-FTC and other crystal formation |
| IL160080A0 (en) | 2001-08-31 | 2004-06-20 | Thomson Licensing Sa | Sequence counter for an audio visual stream |
| WO2003059288A2 (en) | 2002-01-09 | 2003-07-24 | Enzrel, Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| DE14169110T1 (en) | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modified 2' and 3' nucleoside prodrugs for the treatment of Flaviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| TWI244393B (en) | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
| BR0314259A (en) | 2002-09-13 | 2005-07-26 | Idenix Cayman Ltd | ß-l-2'-deoxynucleotides for the treatment of resistant HBV strains and combination therapies |
| KR20050088079A (en) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-branched nucleosides and flaviviridae mutation |
| US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| US20050075309A1 (en) | 2003-07-25 | 2005-04-07 | Richard Storer | Purine nucleoside analogues for treating Flaviviridae including hepatitis C |
| EP1737472B1 (en) | 2004-03-29 | 2014-08-13 | University Of South Florida | Effective treatment of tumors and cancer with triciribine |
| WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| EP1937825B1 (en) | 2005-09-26 | 2016-12-21 | Gilead Pharmasset LLC | Modified 4'-nucleosides as antiviral agents |
| US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2009129120A2 (en) | 2008-04-15 | 2009-10-22 | Rfs Pharma, Llc | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| EA019295B1 (en) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Synthesis of purine nucleosides and process for preparing them |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
| JP2013527145A (en) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | Stereoselective synthesis of phosphorus-containing activators |
| AR084044A1 (en) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | 2’-ESPIRO-NUCLEOSID COMPOUNDS |
| JP6073897B2 (en) | 2011-09-16 | 2017-02-01 | ギリアド ファーマセット エルエルシー | Methods for treating HCV |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| AU2012345732B2 (en) | 2011-11-30 | 2016-07-14 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| ES2771458T3 (en) | 2013-01-31 | 2020-07-06 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| PL3650014T3 (en) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| CN113365607A (en) * | 2019-01-25 | 2021-09-07 | 豪夫迈·罗氏有限公司 | Lipid vesicles for oral drug delivery |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350287A2 (en) * | 1988-07-07 | 1990-01-10 | NeXstar Pharmaceuticals, Inc. | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use |
| WO1991019721A1 (en) * | 1990-06-13 | 1991-12-26 | Arnold Glazier | Phosphorous produgs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291024A (en) * | 1978-04-10 | 1981-09-22 | Turcotte Joseph G | Cytotoxic liponucleotide analogs |
| AU647164B2 (en) * | 1990-05-29 | 1994-03-17 | Nexstar Pharmaceuticals, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
| DE69119074T2 (en) * | 1990-06-15 | 1996-12-12 | University Of North Carolina At Chapel Hill, Chapel Hill, N.C. | COVALENT THER LIPID NUCLEOSIDE CONJUGATES |
-
1992
- 1992-06-03 JP JP5502213A patent/JPH07500573A/en active Pending
- 1992-06-03 CA CA002112803A patent/CA2112803A1/en not_active Abandoned
- 1992-06-03 AU AU22268/92A patent/AU668873B2/en not_active Expired
- 1992-06-03 WO PCT/US1992/004856 patent/WO1993000910A1/en not_active Application Discontinuation
- 1992-06-03 EP EP92914562A patent/EP0594677A4/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0350287A2 (en) * | 1988-07-07 | 1990-01-10 | NeXstar Pharmaceuticals, Inc. | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use |
| WO1991019721A1 (en) * | 1990-06-13 | 1991-12-26 | Arnold Glazier | Phosphorous produgs |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9300910A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2226892A (en) | 1993-02-11 |
| AU668873B2 (en) | 1996-05-23 |
| EP0594677A1 (en) | 1994-05-04 |
| WO1993000910A1 (en) | 1993-01-21 |
| JPH07500573A (en) | 1995-01-19 |
| CA2112803A1 (en) | 1993-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0594677A4 (en) | Antiviral liponucleosides: treatment of hepatitis b | |
| GB2280606B (en) | Physical forms of benzenesulphonamides | |
| GB9127150D0 (en) | Novel treatment | |
| GB2261227B (en) | Surface treatment of metals | |
| GB9104165D0 (en) | Novel entities for hiv therapy | |
| GB9105899D0 (en) | Therapeutic nucleosides | |
| ZA923185B (en) | Therapeutic nucleosides | |
| GB9125891D0 (en) | Antiviral agent | |
| ZA923359B (en) | Treatment of longitudinally extending members | |
| GB9022470D0 (en) | Treatment of clays | |
| ZA932603B (en) | Treatment of hepatitis with GM-CSF | |
| ZA923544B (en) | Antiviral compounds | |
| GB9303719D0 (en) | Antiviral therapy | |
| PH25576A (en) | Antiviral therapy for hepatitis b | |
| GB9117252D0 (en) | Treatment of pollution | |
| GB9125670D0 (en) | Treatment of neurogical conditions | |
| IE880770L (en) | Treatment of viral infections | |
| RU1833739C (en) | Way of treatment hyperekaliemia | |
| GB9124696D0 (en) | Hepatitis c virus | |
| GB8515313D0 (en) | Hepatitis b treatment | |
| GB9111615D0 (en) | Invalid bath | |
| GB9122073D0 (en) | Antiviral agents | |
| HU913223D0 (en) | Okology of man | |
| IE892991L (en) | Treatment of viral infections | |
| GB9212535D0 (en) | Treatment of boimass |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940210 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: VESTAR, INC. |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEXSTAR PHARMACEUTICALS, INC. |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19970801 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19971202 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19980813 |